Casirivimab+Imdevimab

Uses	Covid 19 Disease in High Risk Patients
Therapy	Antiviral
Side Effects	Injection Site Swelling, Pain and Buising, Allergic Reaction

3 Step Quality
Assurance

Cash on delivery
available

NPPA
Regulated

Molecule Description

Casirivimab and imdevimab is a combination of two monoclonal antibodies. It is used for the treatment of confirmed cases of mild to moderate COVID-19 disease in individuals over 12 years of age (weighing at least 40 kg) who are at high risk of developing severe COVID-19 disease and do not require oxygen. High risk is defined as patients over 60 years of age, obesity, existing heart, lung, kidney and liver condition, diabetes, asthma, cancer, HIV, immunocompromised state, someone who has undergone organ transplant and are on medicine that can weaken/suppress the immune system. The use of this medicine should be based on the treating physician's discretion after careful assessment of the condition for an individual patient. This comes as an injection that is given/administered by a healthcare professional either via the intravenous route (takes about 20 to 30 minutes) or subcutaneous route at four different sites on the abdomen or thigh.

Uses

For the treatment of confirmed cases of mild to moderate coronavirus disease in patients over 12 years of age (weighing at least 40 kg) who are at risk of developing serious COVID-19 disease.

Contraindications

When should one not use Casirivimab+Imdevimab

You are hospitalised due to COVID-19 disease and are on oxygen support due to COVID-19 disease.
Individuals requiring an increase in baseline oxygen flow rate due to COVID-19 who are already on oxygen support due to non-COVID-19 related comorbidity.

Side effects

Common side effects of this drug are:

There is limited information available about the side effects of this medicine. Injection site reaction like pain, swelling can occur.
Inform your doctor if you experience fever, chills, nausea, stomach upset, uneven heart rhythm, weakness, confusion, dizziness, chest pain, breathlessness, swelling of lips, face, rash after the infusion.

Precautions and Warnings

Pregnancy

There is limited data available about the safety of this medicine during pregnancy.

Breast Feeding

There are no available data on the safety of this medicine in breastfeeding women and it's not known if the component of this injection pass in breast milk.

Driving

It is not known if this medicine affects your driving abilities. Individuals with COVID-19 disease should stay home in isolation to avoid the spread of infection.

Alcohol

There is no interaction known between alcohol and this medicine.

Other General Warnings

Talk to your doctor if

You experience allergic reactions after taking this injection or have any allergy.
You are pregnant or breastfeeding.
You have any serious medical condition.
You are taking any prescription medicine, supplement or herbals.
Your symptoms worsen and you experience difficulty in breathing, fever, uneven heart rate, fatigue and altered mental status.
This injection should not be used for the treatment of patients who are hospitalized due to COVID-19 disease and are on oxygen support.

Mode of Action

How Does It Work?

This injection contains an antibody cocktail (combination) of two antibodies. Monoclonal antibodies are laboratory-made proteins that imitate the immune system’s ability to fight off harmful pathogens such as viruses. Casirivimab and imdevimab are monoclonal antibodies that work by blocking the attachment of the virus and its entry into human cells.

Interactions

Interactions with other medicines

Tell your doctor about all the medicines, supplements or herbals you are currently taking or might take to avoid any possible interaction.

Frequently Asked Questions (FAQs)

High risk is defined as patients over 60 years of age, obesity, existing heart, lung, kidney or liver condition. Certain medical state such as diabetes, asthma, HIV, cancer, sickle cell anaemia, thalassemia, and prolonged use of immune-weakening medications. This also includes someone who has received a transplanted organ recently, have low or week immunity (immunocompromised).

It is a combination of two man-made antibody or monoclonal antibody combination containing casarivimab and imdevimab. It is authorised to use under emergency condition for the treatment of mild to moderate COVID-19 disease in patients over 12 years of age who are at high risk of developing severe COVID-19 disease.

Tell your doctor if you are pregnant, breastfeeding, have any allergy, serious illness and about any medicines which you are currently taking.

Articles

View All

Did you find this helpful?

References:

Explore More at Pharmeasy

Why trust PharmEasy?

# ONE OF INDIA'S MOST TRUSTED HEALTHCARE PLATFORM

CODAvailable

100%Genuine Medicine

30 DAYReturn Policy

Making medicines affordable, authentic, and easily accessible across India

700+100% Genuine & verified medicines

70,000+Medicine orders everyday

70 MillionTotal customer served

70 MillionDelivery hubs & fulfillment centre

7000Trained & trusted delivery partners